The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study

Published:2022-05 Issue:5 Volume:11 Page:776-785
ISSN:2218-6751
Container-title:Translational Lung Cancer Research
language:
Short-container-title:Transl Lung Cancer Res

Author:

Zhao Yizhuo,Wang Qiming,Zhang Li,Shi Jianhua,Wang Zhehai,Cheng Ying,He Jianxing,Shi Yuankai,Chen Weiqiang,Luo Yi,Wu Lin,Wang Xiuwen,Nan Kejun,Jin Faguang,Dong Jian,Li Baolan,Yamaguchi Fumihiro,Breadner Daniel,Nagano Tatsuya,Tanaka Fumihiro,Husain Hatim,Li Kai,Han Baohui

Publisher

AME Publishing Company

Subject

Oncology

Link

https://tlcr.amegroups.com/article/download/64755/pdf

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial;Signal Transduction and Targeted Therapy;2024-08-13

2. Etoposide soft capsule combined with anlotinib in the third-line treatment of advanced non-small cell lung cancer: a retrospective cohort study;Journal of Thoracic Disease;2023-10

3. Survival benefit of anlotinib in T790M‐positive non‐small‐cell lung cancer patients with acquired osimertinib resistance: A multicenter retrospective study and exploratory in vitro study;Cancer Medicine;2023-06-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP